Chikujee offers a unique opportunity to investors to make an early- stage investment in products and technology that have passed the “proof of principle stage”, thus reducing risk and at the same time accelerating timelines to commercialization

     Short term products will help build solid financial foundation while R&D is being conducted for medium and longer term products

     Funding will be used for start up costs, launching of first line of time and market tested products, completion of animal toxicology studies for the IND submission for ovarian cancer and multiple 505 (b) 2 submissions

     Ovarian cancer is the most lucrative in terms of fast track regulatory approval as well as market capture as the current therapies have not been very successful.   

     Other products will utilize global marketing partners under exclusive license

Multi functional NanoBindi product line is unique in nature and will complete against complex products with an established user base and known brand identity.

          1.    Generics to brand
         2.    Drug life cycle extension
         3.    IP Unlocking.